

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Bhattacharya: New grant review criterion is “not political”
- Population-based cancer surveillance is a national treasure at risk
- Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.
- ACOG says it will no longer accept federal funding